BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome. - Gorombei P; Guidez F; Ganesan S; Chiquet M; Pellagatti A; Goursaud L; Tekin N; Beurlet S; Patel S; Guerenne L; Le Pogam C; Setterblad N; et al. (International journal of molecular sciences, 2021)